1391P - Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer p...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Palliative Care
Palliative and Supportive Care
Surgery and/or Radiotherapy of Cancer
Presenter Santhanam Sundar
Citation Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382
Authors S. Sundar, J. Price, T. Wolfe, D. Thurairasa, E. Shawcroft
  • Dept Of Oncology, Nottingham University Hospitals NHS Trust-City Hospital Campus, NG5 1PB - Nottingham/GB

Abstract

Background

Novel, complex, resource intensive, radiation technology is increasingly used for palliative therapy even though they are not cost effective in poor prognosis pts. (Kim IJROBP 2015;556). Since nearly half of all radiotherapy (RT) activity is palliative (Hoskin Cl Onc 2013;531), objective, validated prognostic tools are urgently needed to guide cost effective utilisation of RT. As advanced cancer is associated with poor nutritional status and immune dysfunction, we assessed prognostic role of PNI-which is based on serum albumin & peripheral blood lymphocytes.

Methods

Mortality of 233 unselected cancer pts treated over a 3 month at Nottingham was assessed. All tumour sites & histology were included. Overall Median age 68 yrs. Sites of RT field: Chest=29% Vertebrae=26% Pelvis=20% Brain=12% Limbs=6% Abd=3% Miscell=3%. 95% completed RT as planned. 93% had stage 4 cancer. PNI available for 131 pts. Majority not suitable for systemic therapy following palliative RT; only 15% and 28% had further hormones and chemo respectively.

Results

Overall Median survival was 5.82 months; 38% died within 90 days of completing RT; Pts with low PNI (

Conclusions

For terminally ill cancer patients, who are not fit for further systemic therapy and whose PNI is 

Clinical trial identification

Legal entity responsible for the study

S Sundar

Funding

None

Disclosure

All authors have declared no conflicts of interest.